Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's NDA for BANZEL� (rufinamide) Oral Suspension (40 mg/mL).

Recently, the US FDA approved Daytrana , Shire's product for treating patients aged between 13 to 17 years suffering from Attention Deficit Hyperactivity Disorder .

Recently, the US FDA approved Daytrana , Shire's product for treating patients aged between 13 to 17 years suffering from Attention Deficit Hyperactivity Disorder .

POZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the U.S. Food and Drug Administration approval of VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application and New Drug Application for VIMOVO to AstraZeneca over the next few weeks.

The list of medications for ADHD/attention deficit disorder with hyperactivity is a long one with new options being added on a regular basis. Fifteen years ago the list of medications for ADHD was a short one, with Ritalin being the shining star. Ritalin is what is known in the medical community as a short term stimulant prescription medication for ADHD. Some suggest that Ritalin was rushed to the market. They point to the fact that it was not unanimously approved for safety by the FDA, but none